Zobrazeno 1 - 10
of 54
pro vyhledávání: '"G A Omura"'
Autor:
Lesley A. Stewart, S. B. Kaye, S. Pecorelli, N. Colombo, C. Mangioni, R. V. Smalley, B. Y. Yeap, D. W. Wilbur, R. C. Leonard, M. F. Brady, E. Wiltshaw, P. F. Conte, S. Marsoni, J. F.G. Sturgeon, M. H.N. Tattersall, C. Gennatas, C. Trope, A. Athanazziou, D. Guthrie, D. Crowther, D. R. Bell, A. H. Laing, M. Gore, J. B. Vermorken, C. Lewis, E. Gilbey, Giorgio Bolis, H. Bruckner, P. Adnitt, M. K.B. Parmar, M. Tomirotti, H. Meerpohl, H. S. Brodovsky, W. Sauerbrei, J. Pater, R. Canetta, W.W. ten Bokkel Huinink, D. V. Skarlos, H. J. Solomon, M. J. Webb, J. T. Wharton, F. Landoni, P. Y. Liu, M. M. Turbow, J. H. Edmonson, D. S. Alberts, C. J. Cohen, K. Aabo, W. Torri, V. Barley, M. Adams, M. Buyse, C. J. Williams, M. Presti, V. Chylak, U. Bianchi, G. A. Omura
Publikováno v:
Scopus-Elsevier
The purpose of this systematic study was to provide an up to date and reliable quantitative summary of the relative benefits of various types of chemotherapy (non-platinum vs platinum, single-agent vs combination and carboplatin vs cisplatin) in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2151ac8be4c1ee28ab74e9cc655baa87
https://doi.org/10.1038/bjc.1998.710
https://doi.org/10.1038/bjc.1998.710
Autor:
D. C. Ihde, A. M. Fremgen, J. M. Cain, D. Lowy, M. R. Henry, A. H. Epstein, B. L. Andersen, J. R. Lunney, P. W. Grigsby, D. K. Ash, J. Ruffin, M. H N Tattersall, M. F. Mitchell, H. W. Lawson, Frederick Stehman, R. C. Park, C. McNeil, P. J. Hitchcock, B. S. Kramer, J. F. Magrina, J. M. Elliott, M. A. Penalver, W J Jr Spanos, A. S. Lichter, R. S. Berkowitz, R. M. Lanciano, P. E. Saigo, J. H. Ferguson, I. Gage, M. A. Steller, C. Nichols, P. S. Braly, Carol L. Brown, C. P. Hunter, R. L. Sweet, J. L. Bader, M. E. Randall, K. D. Hatch, W. H. Hall, V. W. Pinn, J. Overgaard, G L Sr Eddy, A. H. Rusell, D. Kapp, G. A. Omura, A. E. Howes, M. Morris, D. G. Petereit, J. A. Benda, J. S. Hutchison, P. J. Eifel, A. F. Saftlas, R. Herrero, H. M. Keys, S. Scherr, N. Munoz, G. M. Thomas
Publikováno v:
Gynecologic Oncology. 66:351-361
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::980a2fe1244b60f86f50edbc306df815
https://doi.org/10.1006/gyno.1997.4849
https://doi.org/10.1006/gyno.1997.4849
Autor:
N L, Bartlett, G R, Petroni, B A, Parker, N D, Wagner, J P, Gockerman, G A, Omura, G P, Canellos, M, Robert, J L, Johnson, B A, Peterson
Publikováno v:
Cancer. 92(2)
To address the feasibility and outcome of moderate dose intensification with granulocyte-colony stimulating factor (G-CSF) for patients with aggressive non-Hodgkin lymphoma (NHL), the Cancer and Leukemia Group B (CALGB) conducted two studies evaluati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a856d31ca78771d896600d3f1a896ba9
https://pubmed.ncbi.nlm.nih.gov/11466671
https://pubmed.ncbi.nlm.nih.gov/11466671
Autor:
G A, Omura
Publikováno v:
Journal of the National Cancer Institute. Monographs. (21)
Numerous drugs and drug combinations have been evaluated, largely in phase II trials, for the treatment of carcinoma of the uterine cervix. There clearly is a need for effective chemotherapy for this disease, but the results to date have unfortunatel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c86fe374dad1fca69b44975de6aa0cce
https://pubmed.ncbi.nlm.nih.gov/9023841
https://pubmed.ncbi.nlm.nih.gov/9023841
Publikováno v:
Leukemia. 9(9)
A phase III clinical trial was designed to determine if more intensive induction and consolidation therapy for acute myeloblastic leukemia increases the remission rate and prolongs survival. A minor objective was to determine if the use of non-cross
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1c3e30570a9dda8c454ed5cc55982294
https://pubmed.ncbi.nlm.nih.gov/7544851
https://pubmed.ncbi.nlm.nih.gov/7544851
Publikováno v:
Leukemia. 8(11)
A phase III clinical trial was developed to test whether the addition of etoposide to a high-dose cytosine arabinoside regimen would improve the remission rate, duration of remission, and survival in relapsed and refractory patients with acute myelog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e948d2b46c0e23315210f4f850dee9df
https://pubmed.ncbi.nlm.nih.gov/7967730
https://pubmed.ncbi.nlm.nih.gov/7967730
Autor:
R J, Mayer, R B, Davis, C A, Schiffer, D T, Berg, B L, Powell, P, Schulman, G A, Omura, J O, Moore, O R, McIntyre, E, Frei
Publikováno v:
The New England journal of medicine. 331(14)
About 65 percent of previously untreated adults with primary acute myeloid leukemia (AML) enter complete remission when treated with cytarabine and an anthracycline. However, such responses are rarely durable when conventional postremission therapy i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::feee2e6012cb05c1fbb025734f577b56
https://pubmed.ncbi.nlm.nih.gov/8078557
https://pubmed.ncbi.nlm.nih.gov/8078557
Autor:
G A, Omura
Publikováno v:
Seminars in oncology. 21(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2b12d57ebdb38cd5691a15c46843b0c1
https://pubmed.ncbi.nlm.nih.gov/8310310
https://pubmed.ncbi.nlm.nih.gov/8310310
Autor:
G A, Omura
Publikováno v:
Oncology (Williston Park, N.Y.). 6(4)
There clearly is a need for effective chemotherapy for early-stage, high-risk patients with carcinoma of the uterine cervix, and for those with advanced disease. Results to date have been disappointing. Cisplatin is active but overrated. Ifosfamide a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::98ef23b68c519147220314a60e2e8593
https://pubmed.ncbi.nlm.nih.gov/1533780
https://pubmed.ncbi.nlm.nih.gov/1533780
Publikováno v:
American journal of clinical oncology. 14(4)
In a multicenter trial, we evaluated the antiemetic efficacy of ondansetron, a selective serotonin type 3 (5-HT3) receptor antagonist, in 42 adult chemotherapy-naïve patients receiving a multiple-day cisplatin regimen (20-40 mg/m2 per day for 4-5 da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a79b1824e7e808c27911d591097244c3
https://pubmed.ncbi.nlm.nih.gov/1830716
https://pubmed.ncbi.nlm.nih.gov/1830716